|
[1]WU HD, ZHOU HJ, WANG ZH.Application of direct-acting antiviral agents in patients with severe chronic renal insufficiency complicated by hepatitis C virus infection[J].Chin J Nephrol, 2017, 33 (1) :69-72. (in Chinese) 吴杭迪, 周惠娟, 王朝晖.直接抗病毒药物在重度慢性肾功能不全合并丙型肝炎病毒感染人群中的应用[J].中华肾脏病杂志, 2017, 33 (1) :69-72.
|
|
[2]LI MR, XU XY.Recent progress in direct-acting antiviral agents for chronic hepatitis C[J].J Clin Hepatol, 2014, 30 (6) :493-495. (in Chinese) 李敏然, 徐小元.抗HCV小分子化合物的研究[J].临床肝胆病杂志, 2014, 30 (6) :493-495.
|
|
[3]COPPOLA N, MINICHINI C, STARACE M, et al.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals[J].J Med Virol, 2016, 88 (10) :1659-1671.
|
|
[4]SUDA G, OGAWA K, KIMURA M, et al.Novel treatment of hepatitis C virus infection for patients with renal impairment[J].J Clin Transl Hepatol, 2016, 4 (4) :320-327.
|
|
[5]SMOLDERS EJ, de KANTER CT, van HOEK B, et al.Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment[J].Drug Saf, 2016, 39 (7) :589-611.
|
|
[6]ROTH D, NELSON DR, BRUCHFELD A, et al.Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) :a combination phase 3study[J].Lancet, 2015, 386 (10003) :1537-1545.
|
|
[7]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
|
[8]POCKROS PJ, REDDY KR, MANTRY PS, et al.Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J].Gastroenterology, 2016, 150 (7) :1590-1598.
|
|
[9]CHOLONGITAS E, PIPILI C, PAPATHEODORIDIS GV.Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation[J].World J Hepatol, 2017, 9 (4) :180-190.
|
|
[10]LIN CW, DUTTA S, DING B, et al.Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy white, Chinese, and Japanese adult subjects[J].J Clin Pharmacol, 2017, 57 (12) :1616-1624.
|
|
[11]GANE E, LAWITZ E, PUGATCH D, et al.Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment[J].N Engl J Med, 2017, 377 (15) :1448-1455.
|
|
[12]KUMADA H, WATANABE T, SUZUKI F, et al.Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection[J].J Gastroenterol, 2017.[Epub ahead of print]
|
|
[13]GARIMELLA T, WANG R, LUO WL, et al.Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment[J].Antivir Ther, 2015, 20 (5) :535-543.
|
|
[14]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.
|
|
[15]ELEY T, GARIMELLA T, LI W, et al.Asunaprevir:a review of preclinical and clinical pharmacokinetics and drug-drug interactions[J].Clin Pharmacokinet, 2015, 54 (12) :1205-1222.
|
|
[16]SUDA G, KUDO M, NAGASAKA A, et al.Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C[J].J Gastroenterol, 2016, 51 (7) :733-740.
|
|
[17]OUWERKERK-MAHADEVAN S, BEUMONT-MAUVIEL M, MORTIER S, et al.Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment[J].Drugs R D, 2015, 15 (3) :261-270.
|
|
[18]SORIANO V, BENITEZ-GUTIERREZ L, ARIAS A, et al.Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C[J].Expert Opin Drug Metab Toxicol, 2017, 13 (9) :1015-1022.
|
|
[19]SAXENA V, KORAISHY FM, SISE ME, et al.Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function[J].Liver Int, 2016, 36 (6) :807-816.
|
DownLoad: